menu search

VBLT / UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open. Professor Dror Harats, M.D., Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update. Read More
Posted: Mar 14 2022, 09:57
Author Name: GlobeNewsWire
Views: 102124

VBLT News  

Penny Stocks To Buy? 10 Under $1 To Watch This Week

By PennyStocks
April 19, 2023

Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy? more_horizontal

Penny Stocks To Buy? 7 Under $1 To Watch This Week

By PennyStocks
April 17, 2023

Penny Stocks To Buy? 7 Under $1 To Watch This Week

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy? more_horizontal

Penny Stocks To Buy: 5 To Watch Before Next Week

By PennyStocks
March 1, 2023

Penny Stocks To Buy: 5 To Watch Before Next Week

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Info more_horizontal

Why Is Vascular Biogenics (VBLT) Stock Up 52%?

By InvestorPlace
February 23, 2023

Why Is Vascular Biogenics (VBLT) Stock Up 52%?

Vascular Biogenics (NASDAQ: VBLT ) stock is rocketing higher on Thursday following news of a merger with Notable Labs. The details of the deal include more_horizontal

Why Vascular Biogenics Stock Is Plunging

By Benzinga
July 20, 2022

Why Vascular Biogenics Stock Is Plunging

Vascular Biogenics Ltd (NASDAQ: VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec more_horizontal

Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 17, 2022

Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the number more_horizontal

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 23, 2022

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript more_horizontal

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

By GlobeNewsWire
March 14, 2022

UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused more_horizontal


Search within

Pages Search Results: